Zura Bio Limited Class A Ordinary Shares (NASDAQ:ZURA) — Market Cap & Net Worth
Market Cap & Net Worth: Zura Bio Limited Class A Ordinary Shares (ZURA)
Zura Bio Limited Class A Ordinary Shares (NASDAQ:ZURA) has a market capitalization of $235.38 Million ($235.38 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15994 globally and #3728 in its home market, demonstrating a -1.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zura Bio Limited Class A Ordinary Shares's stock price $3.62 by its total outstanding shares 65023308 (65.02 Million). Review Zura Bio Limited Class A Ordinary Shares total liabilities to assess the company's total debt and financial obligations.
Zura Bio Limited Class A Ordinary Shares Market Cap History: 2023 to 2026
Zura Bio Limited Class A Ordinary Shares's market capitalization history from 2023 to 2026. Data shows change from $303.66 Million to $235.38 Million (-22.15% CAGR).
Index Memberships
Zura Bio Limited Class A Ordinary Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.01% | #433 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1557 of 3165 |
Weight: Zura Bio Limited Class A Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zura Bio Limited Class A Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zura Bio Limited Class A Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ZURA by Market Capitalization
Companies near Zura Bio Limited Class A Ordinary Shares in the global market cap rankings as of June 19, 2026.
Key companies related to Zura Bio Limited Class A Ordinary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Zura Bio Limited Class A Ordinary Shares Historical Marketcap From 2023 to 2026
Between 2023 and today, Zura Bio Limited Class A Ordinary Shares's market cap moved from $303.66 Million to $ 235.38 Million, with a yearly change of -22.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $235.38 Million | -30.92% |
| 2025 | $340.72 Million | +109.60% |
| 2024 | $162.56 Million | -46.47% |
| 2023 | $303.66 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Zura Bio Limited Class A Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $235.38 Million USD |
| MoneyControl | $235.38 Million USD |
| MarketWatch | $235.38 Million USD |
| marketcap.company | $235.38 Million USD |
| Reuters | $235.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more